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Abstract
Giant cell arteritis (GCA), also known as temporal arteritis or Horton disease, 
is categorized as a large- and medium-sized vessels vasculitis. Systemic symptoms 
are common in GCA and although vascular involvement may be widespread, the 
cranial branches of the aortic arch are responsible for the hallmark symptoms of 
GCA: headache, jaw claudication and ocular symptoms, particularly visual loss. 
The large vessel (LV)-GCA phenotype may differ or overlap from cranial arteritis. 
Clinical consequences of LV-GCA comprise aneurysms and dissections of the aorta, 
as well as stenosis, occlusion and ectasia of large arteries. Symptoms of polymy-
algia rheumatica occurring in a patient with GCA include characteristic proximal 
polyarthralgias and myalgias, sometimes accompanied by remitting seronegative 
symmetrical synovitis with pitting edema (RS3PE), Less common manifestations 
reported include central nervous system involvement, audiovestibular and upper 
respiratory symptoms, pericarditis, mesenteric ischemia and female genital tract 
involvement.
Keywords: systemic symptoms, cranial arteritis, headaches, visual disturbance, 
vision loss, polymyalgia rheumatica, RS3PE, large vessel phenotype
1. Introduction
Giant cell arteritis (GCA), also known as temporal arteritis or Horton disease, is 
a systemic inflammatory large-vessel vasculitis that usually affects the aorta and its 
major branches [1].
The pathophysiology of GCA is complex and not fully understood. 
Histopathology studies reveal inflammation of the artery wall with predominance 
of CD4+ T lymphocytes and macrophages, which frequently undergo granuloma-
tous organization with formation of giant cells. Immunopathology and molecular 
studies performed with temporal artery biopsies have led to the current pathogenic 
model [2],
GCA is primarily an immune-mediated disease due to a maladaptive response 
to endothelial injury, occurring in susceptible individuals and triggered by factors 
that have not been identified with certainty. Several microbe and viral sequences, 
including varicella-zoster virus, have been detected in temporal artery lesions, but 
no convincing causal relationship has been demonstrated [3].
The initial inflammatory response involves the activation of dendritic cells, 
present in the adventitia of normal arteries, through pathogen- or damage-sensing 
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receptors, such as toll-like receptors, producing chemokines able to attract and 
retain dendritic cells as well as lymphocytes and macrophages. Once activated, 
dendritic cells are enabled to process and present antigens and strongly express 
major histocompatability complex (MHC) class II and costimulatory molecules 
(CD83 and CD86) required for T-cell recruitment [4].
Once activated, both T helper (Th)1 and Th17 differentiation pathways con-
tribute to the development of vascular inflammation. Interleukin (IL)-12 and 
IL-18 produced by dendritic cells stimulate Th1 differentiation and production of 
interferon (IFN)-gamma which is noticeably expressed in GCA-involved arteries. 
IFN-gamma causes endothelial cells and vascular smooth muscle to recruit more 
Th1 cells, CD8+ T cells, and monocytes which differentiate into macrophages and 
the characteristic giant cells that produce growth factors, interleukins and proteo-
lytic enzymes playing a distinctive role granuloma formation that progressively 
narrow and obstruct the vessel wall [5].
Moreover, IL-1-beta, IL-6, and IL-21 promote Th17 differentiation, which is 
maintained by IL-23 and results in IL-17A expression. IL-17A, profusely expressed 
in GCA lesions, is a proinflammatory cytokine having pleiotropic effects on a 
variety of cells, namely macrophages, fibroblasts, endothelial cells and vascular 
smooth muscle cells [6].
Systemic manifestations are related the inflammatory process and cytokine amplifi-
cation. Inflammation-induced vascular remodeling leads to concentric intimal hyper-
plasia occurring as a repair mechanism in response to injury of the blood vessel wall. 
End-organ involvement results from mural hyperplasia which can narrow the arterial 
lumen, resulting in distal ischemia and ischemic complications of the disease [7].
2. Clinical manifestations of giant cell arteritis
Clinical presentation of GCA tends to be subacute, but may occur over the 
course of a few days. Although symptoms of GCA are nonspecific, some key 
findings may strongly suggest this diagnosis. Systemic symptoms are common in 
GCA and vascular involvement can be widespread, causing stenosis and aneurysm 
of affected vessels. It is the targeting of the tiny muscular arteries from cranial 
branches of the aortic arch, however, that gives rise to many of the most character-
istic symptoms of GCA. External carotid branch involvement accounts for the high 
frequency of cranial symptoms [8].
2.1 Constitutional symptoms
Systemic symptoms associated with GCA are frequent and include fever, fatigue, 
anorexia and weight loss. These symptoms may occur for a few days and may 
prolong to several weeks. Fever is usually low grade and occurs in up to one-half of 
patients. It has been stated as well that 1 out of 6 fevers of unknown origin in older 
adults was due to GCA [9]. About 10% of patients with GCA present with constitu-
tional symptoms and laboratory evidence of inflammation as the only clues to the 
diagnosis [10]. Thus, in an older adult with fever or constitutional symptoms not 
explained by an initial evaluation for infection or malignancy, a diagnosis of GCA 
warrants consideration [11].
2.2 Headache
Headache is a common presentation of GCA, being the initial symptom in 33% 
of cases and present in about 80% of patients [12]. Importantly, the headache is 
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either new, in a patient without previous history of headaches, or of a new type in a 
patient with chronic headache.
While the headache has no pathognomonic features, headaches due to GCA are 
typically throbbing and continuous, located over the temples, but can also be fron-
tal, occipital, unilateral or generalized. Descriptions of the pain range from a dull or 
burning sensation to focal tenderness on direct palpation. Patients may note scalp 
tenderness with hair combing or when wearing a hat. The headache can progres-
sively worsen, wax and wane, or sometimes recede before treatment is started [13].
2.3 Jaw claudication
Jaw claudication results from ischemia of the maxillary artery supplying the 
masseter muscles and is highly predictive of temporal arteritis. Nearly 50% of 
patients experience jaw claudication, a symptom consisting of mandibular pain, 
discomfort or fatigue triggered by mastication or prolonged speaking and relieved 
by stopping [14]. An analysis of the diagnostic value of temporal artery biopsies, 
which correlated positive biopsies with clinical symptoms, revealed jaw claudica-
tion as the symptom most highly associated with a positive biopsy [15].
In some cases, patients note a trismus-like symptom, with either perceived or 
actual limitation of temporomandibular joint excursion. Claudication symptoms 
occasionally affect the tongue, with repeated swallowing and tongue infarction 
being almost pathognomonic for GCA [16, 17].
2.4 Ocular involvement
The reported incidence of visual symptoms in GCA ranges widely [18]. These 
include permanent visual loss, transient monocular (and, rarely, binocular) 
vision impairment, consisting of unilateral visual blurring, vision loss or diplopia. 
Patients refer an abrupt partial field defect or temporary curtain effect in the field 
of vision of one eye [19]. It can be useful in the course of evaluating the possible 
significance of a reported visual disturbance to inquire if the patient tried to cover 
each eye since explicit monocular visual loss would heighten concern for GCA. 
Transient visual loss can be a harbinger of permanent visual loss, especially if 
treatment is not started promptly and thus mandates urgent attention in a patient 
with suspected GCA.
The most feared complication of GCA is permanent loss of vision, frequently 
sudden and painless, may be partial or complete, and may be unilateral or bilateral. 
Permanent loss of vision in GCA results from arteritic anterior ischemic optic neu-
ropathy, central or branch retinal artery occlusion, posterior ischemic optic neu-
ropathy, or, rarely, cerebral ischemia [20]. Even in the current era effective therapy, 
the incidence of permanent loss of vision ranged from 15 to 20% of patients [20]. 
Though permanent visual loss may be preceded by single or multiple episodes of 
transient visual loss, it can also occur with devastating swiftness. When untreated, 
contralateral eye involvement commonly occurs between the first two weeks after 
initial onset [21]. With adequate glucocorticoid treatment, if there is no further 
visual deterioration within the first week, existing vision in affected eye and the 
vision in the unaffected eye will remain intact, virtually stopping the subsequent 
risk of sight loss [22].
Extraocular motility disorders occur in approximately 5% of atients and include 
diplopia which has a high specificity when accompanied by other symptoms sugges-
tive of GCA [23]. Diplopia, which is usually transient, can result from ischemia of 
any portion of the oculomotor system, including the brainstem, oculomotor nerves, 
and the extraocular muscles themselves [24].
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Although rare, GCA can manifest with Charles Bonnet syndrome, a phenom-
enon of visual hallucinations in psychologically normal individuals who have visual 
loss due to lesions in either peripheral or central visual pathways [25].
2.5 Musculoskeletal involvement
GCA is closely linked to polymyalgia rheumatica (PMR) and this well-known 
association has therapeutic and prognostic consequences. About 40 to 60% of GCA 
patients have manifestations of PMR, an inflammatory rheumatic condition clinically 
characterized by symmetrical proximal polyarthralgia and myalgia, with aching and 
stiffness on shoulders, hip girdle, neck, torso and an unfamiliar sense of fatigue [26].
Less commonly, distal findings can occur, involving synovitis of peripheral 
joints, especially at the wrists and metacarpophalangeal joints, with distal extremity 
swelling and pitting edema, known as remitting seronegative symmetrical synovitis 
with pitting edema (RS3PE) syndrome, puffy edematous hand syndrome or distal 
extremity swelling with pitting edema [27]. In this syndrome symptoms can appear 
abruptly, with significant swelling, usually pitting, extending over the dorsal side of 
the wrists and metacarpophalangeal joints producing a “boxing glove” appearance, 
and with limited range of motion of the hands and wrists. The term seronegative 
refers to the absence of antibodies namely rheumatoid factor (RF) and cyclic citrul-
linated peptide (anti-CCP) for differential diagnosis with rheumatoid arthritis. 
Imaging with ultrasonography and MRI reveal tenosynovitis of the extensor tendon 
of the forearms and hands, with less flexor tenosynovitis and synovitis of the 
metacarpophalangeal and proximal interphalangeal joints [28]. A paraneoplastic 
association with solid tumors and hematologic disorders has been reported, but in 
clinical practice such an occurrence is rare [29].
2.6 Large vessel involvement
Involvement of the extracranial branches of the carotid artery is the source of 
the classic cranial symptoms of GCA. However, besides the carotid arteries, GCA 
often involves the aorta and its major branches which is designated large vessel (LV) 
-GCA. The clinical consequences of LV-GCA include aneurysms and dissections of 
the aorta, particularly the thoracic aorta, as well as stenosis, occlusion, and ectasia 
of large arteries. This subset of patients with predominantly upper extremity arte-
rial vasculitis, may have variable clinical presentations and diagnostic delay [30].
While symptomatic LV involvement is uncommon, a key point is that subclinical 
LV-GCA involvement is present in a significant number of patients and can underlie 
a systemic presentation of GCA without having necessarily cranial symptomatol-
ogy. Different publications using imaging modalities such as fluorodeoxyglucose 
positron emission tomography (FDG-PET), computed tomographic (CT) angiog-
raphy and color-coded duplex ultrasonography have consistently highlighted the 
involvement of subclavian, axillary, brachial arteries or the thoracic aorta in more 
than 30% of patients with confirmed GCA diagnosis [31, 32].
Although the disease pattern of LV-GCA differs from cranial GCA, clinical 
features overlap. Systematic screening of patients with the cranial phenotype can 
demonstrate large artery involvement. On the other hand, temporal artery biopsies 
are positive in only approximately one-half of patients with LV GCA, underlining 
the essential role of imaging for the diagnosis of this phenotype.
In contrast with the cranial phenotype, LV-GCA patients were younger at disease 
onset (66 vs. 72 years), had longer duration of symptoms prior to the diagnosis 
(median 3.5 months vs. 2.2 months), fewer cranial symptoms (41% vs. 83%) and 
were more likely to have arm claudication at presentation (51% vs. 0%) [33].
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Aortic aneurysms have been recognized in 10% of cases [34]. The thoracic aorta 
is more frequently affected than the abdominal aorta, and within the thoracic aorta 
the descending segment is the main site. It is important to note that in these cases, 
there is often little or no clinical or laboratory evidence of systemic activity of GCA. 
When compared with the general population, patients with GCA have a twofold 
increased risk of aortic aneurysm and this should be considered within the range of 
other risk factors such as male gender, age or smoking [35]. Histopathologic exami-
nation of specimens from surgery or autopsy show fibrosis and different degrees 
of active aortitis, including giant cells. These findings suggest two mechanisms 
of disease: chronic recrudescent aortitis causing elastin and collagen disruption, 
or mechanical stress on an aortic wall weakened in the early active phase of the 
disease. Aortic dissection or rupture is a rare major complication of aortitis and was 
identified in 5% of patients with LV-GCA with aortic aneurysm [36]. Involvement 
of the ascending aorta can lead to aortic rupture, and coronary arteritis may result 
in myocardial infarction.
GCA can also affect the subclavian arteries distal to the take-off of the vertebral 
arteries and extend through the axillary arteries to the proximal brachial arteries. 
On physical examination, arterial bruits, diminished or absent blood pressures 
and arm claudication can be identified. Cold intolerance of the involved extrem-
ity is common, but explicit digital ulcerations and gangrene are rare because of 
adequate collateral arterial supply. The vessel wall is circumferentially affected, in 
contrast to the eccentric appearance of atherosclerosis. The descending aorta and 
mesenteric, renal, iliac, and femoral arteries can less commonly be affected, with 
attendant complications of intestinal infarction, renal infarction, crural infarction 
and ischemic mononeuropathies [37]. Clinically evident lower-extremity arterial 
involvement can occur but is also uncommon [38].
2.7 Central nervous system involvement
Stroke is a rare but important complication of GCA and is typically due to 
stenosis of carotid and the vertebral or basilar arteries. Even with aggressive steroid 
and immunosuppressive therapy it is associated with high morbidity and mortality. 
In descriptive cohorts, the frequency of stroke within the first four weeks of the 
diagnosis of GCA, and thus construed as potentially disease-related, has ranged 
from 1.5 to 7.5% [39].
Though strokes due to GCA can occur in the distribution of both the internal 
carotid and vertebrobasilar arteries, they are noticeably more frequent in the 
latter location. More than one-half of strokes attributable to GCA occur in the 
vertebrobasilar system This figure contrasts with population-based studies of 
transient ischemic attacks and stroke overall, which occur five times more often 
in the territory of the internal carotid arteries compared with the vertebrobasilar 
arteries [40]. Arteritic involvement of the vertebral arteries can result in vertigo, 
ataxia, dysarthria, homonymous hemianopsia, or bilateral cortical blindness. 
Bilateral vertebral artery involvement, which causes rapidly progressive brainstem 
or cerebellar neurologic deficits with high mortality, is highly suggestive of GCA.
Peripheral neuropathy, myelopathy, higher cortical dysfunction or dementia, 
and pachymeningitis are uncommon complications of GCA.
2.8 Respiratory tract symptoms
Patients with GCA can present upper respiratory tract symptoms, in par-
ticular a non-productive cough. The cause of cough is unknown, but may result 
from vasculitis in the area of cough receptors, which are located throughout the 
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respiratory tree, or vasculitis of the ascending pharyngeal artery, a branch of the 
external carotid artery. Vasculitis of the bronchial arteries has been observed in 
the post-mortem examination of a patient with disseminated GCA. Furthermore, 
involvement of the lungs in GCA has also been reported as cases of interstitial lung 
disease (ILD) as an uncommon clinical manifestation of GCA [41].
2.9 Cardiac involvement
Patients with GCA are at increased risk for cardiovascular events, but cardiac 
involvement is rare. Myocardial infarction is an example of serious complication 
that may arise. Cases of GCA patients developing myocarditis and myopericarditis 
are uncommon but have been reported [42].
2.10 Head and neck involvement
Branches of the external carotid artery may often be affected in GCA, namely 
the superficial temporal artery. Jaw claudication results from arteritic involvement 
of the muscles of mastication (masseter, temporalis, and medial and lateral ptery-
goid muscles), all of which are supplied by the branches of the external carotid 
artery. Involvement of other branches of the external carotid artery accounts for 
many of the other extracranial symptoms that can accompany the presentation of 
GCA, including: maxillary and dental pain, facial swelling, throat pain, tongue pain 
and macroglossia [43].
2.11 Atypical features
GCA of the female genital tract was first reported by Ritawa in 1951 [44]. Female 
genital tract involvement (ovary, fallopian tubes, or uterus) was identified by 
chance on histopathologic inspection of surgical specimens surgically removed for 
gynecological reasons unrelated to GCA.
Vasculitis of the breast does occur and should require exclusion of systemic 
involvement. When constitutional symptoms, especially arthralgia and myalgia, are 
present and acute phase reactants are elevated, a work-up for systemic disease is espe-
cially warranted. Histologic characteristics included vessel size and type of inflamma-
tory infiltrates including foamy macrophages and giant cells [45]. These features did 
not correlate with disease extent, plus constitutional and musculoskeletal manifesta-
tions were usually absent. Patients generally did not require systemic therapy and may 
be cured by resection alone.
3. Conclusion
GCA should always be considered in the differential diagnosis of a new-onset 
headache in patients 50 years of age or older with an elevated erythrocyte sedimen-
tation rate. Temporal artery biopsy remains the criterion standard for diagnosis of 
this granulomatous vasculitis but increasing evidence supports the use of imaging 
studies such as ultrasonography as a less invasive from of diagnosis.
The onset of symptoms in GCA tends to be subacute, but abrupt presentations 
occur in some patients. Although systemic manifestations are characteristic of GCA 
and although vascular involvement can be widespread, clinical manifestations of 
the disease most frequently result from involvement of the cranial branches of 
arteries originating from the aortic arch. When taking the patient’s history, the 
clinician must ask about the following types of symptoms: systemic symptoms, such 
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as fever, fatigue, and weight loss; headache; jaw claudication, which is the symptom 
most highly predictive of a positive temporal artery for the diagnosis of GCA; visual 
symptoms, particularly transient monocular visual loss and diplopia. The most 
threatening complication of GCA, visual loss, is a potential result of the cranial 
phenotype arteritis.
A close relationship exists between GCA and PMR but the precise nature of 
this association is poorly understood. Several authors have suggested that these 
two entities are actually different stages of the same disease process. Symptoms 
of polymyalgia rheumatica occurring in a patient with GCA include characteristic 
proximal polyarthralgias and myalgias, sometimes accompanied by remitting 
seronegative symmetrical synovitis with pitting edema (RS3PE).
Most GCA patients present with clinical manifestations that are the result of 
vascular involvement but a variable proportion of patients may present without 
obvious vascular manifestations. Imaging may be particularly helpful in the 
diagnosis of GCA of large arteries in patients with atypical or occult GCA disease. 
Subclinical involvement of the aorta and large arteries is frequent, a clinical con-
sequence of which can be aortic aneurysm which rarely can be complicated with 
dissection or rupture. Measurement of the blood pressures in both arms and careful 
assessment of the arterial tree by palpation and auscultation should be performed 
in all patients with suspected GCA. When compared with cranial disease, LV-GCA 
patients have higher relapse rate, greater corticosteroid requirements and increased 
prevalence of aortic aneurysm. It should be noted that both the 1990 and the 
revised 2016 American College of Rheumatology criteria may fail to recognize the 
LV-GCA phenotype, since a portion of LV-GCA do not have cranial symptoms.
The major risk factor for developing giant cell arteritis is aging. The disease 
almost never occurs before age 50 years, and its incidence rises steadily thereafter. 
Giant cell arteritis is a more heterogeneous condition than previously thought. 
Clear knowledge of all the potential clinical manifestations is essential to avoid a 
delayed diagnosis and associated complications. Although most of these manifesta-
tions occur prior to steroid therapy, they may also develop during the early phase 
of therapy or relapse with tapering of the dose of steroids. Earlier diagnosis, close 
monitoring and improving the treatment protocols may prevent mortality and 
improve morbidity in these cases.
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